Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 7c, Beats on Revenue

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $96.04 million versus the consensus estimate of $92.24 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Goldman Sachs Assumes Krystal Biotech (KRYS) at Buy
• S&P 500 history shows strong gains across Fed hiking cycles: BCA
• Piper Sandler on General Mills (GIS): 'Innovating To Grow'